

Special Issue

Multiple Signaling Pathways in Ovarian Cancer

Message from the Guest Editors

Scope: Molecular pathways responsible for mesenchymal transformation and chemoresistance.

Aims: This Special Issue aims to provide a platform for new findings related to the tumor microenvironment and the molecular pathways associated with ovarian cancer progression and chemoresistance. In this Special Issue, both original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Molecular signals originating from the tumor microenvironment responsible for the process of mesenchymal transformation;
- The role of exosomes in the transformation of ovarian cancer cells;
- The influence of the stroma on malignant progression;
- Adipocytes and their role in malignant progression;
- Metabolic adaptation and pathways conferring mesenchymal transformation;
- The role of the signals initiated in the microenvironment responsible for chemoresistance;
- Inflammatory signals and malignant progression.

Guest Editors

Dr. Gil Mor

Department of Obstetrics and Gynecology, C.S. Mott Center for Human Growth and Development, Wayne State University, Detroit, MI 48201, USA

Prof. Dr. Ayesha B. Alvero

Department of Obstetrics and Gynecology, C.S. Mott Center for Human Growth and Development, Wayne State University, Detroit, MI 48201, USA

Deadline for manuscript submissions

closed (31 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/147242

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)